PMID- 34128337
OWN - NLM
STAT- MEDLINE
DCOM- 20211221
LR  - 20221207
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 12
IP  - 15
DP  - 2021 Aug
TI  - Neoantigen load as a prognostic and predictive marker for stage II/III non-small 
      cell lung cancer in Chinese patients.
PG  - 2170-2181
LID - 10.1111/1759-7714.14046 [doi]
AB  - BACKGROUND: The prognosis for patients with stage II/III non-small cell lung 
      cancer (NSCLC) is unsatisfactory, even after complete tumor resection and 
      adjuvant chemotherapy. Here, we assessed the prognostic and predictive value of 
      immunogenomic signatures for stage II/III NSCLC in Chinese patients. METHODS: A 
      total of 91 paired resected stage II/III NSCLC and normal tissues, including 47 
      squamous cell lung carcinomas (SCC) and 44 lung adenocarcinomas (ADC), were 
      collected and analyzed using whole exome sequencing (WES) to identify 
      immunogenomic signatures for association with clinicopathological variables and 
      disease-free survival (DFS). RESULTS: Higher neoantigen load (NAL, >2 
      neoantigens/Mb) exhibited better DFS for SCC patients (p = 0.021) but not ADC 
      patients. A benefit from adjuvant chemotherapy was correlated with lower NAL (</=2 
      neoantigens/Mb) (p = 0.009). However, tumor mutation burden (TMB), mutations of 
      individual gene, oncogene pathways, and antigen presentation machinery genes, and 
      human leukocyte antigen (HLA)-I number and HLA-I loss of heterozygosity (LOH) had 
      no prognostic or predictive value for DFS of SCC or ADC patients. CONCLUSIONS: 
      NAL is a useful biomarker for lung SCC prognosis and prediction of chemotherapy 
      responses in Chinese patients. The predictive value of NAL for adjuvant 
      immunotherapy should be further explored in patients with resected NSCLC.
CI  - (c) 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Gong, Lei
AU  - Gong L
AD  - Department of Medical Oncology, The Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital) and Institute of Basic Medicine 
      and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - He, Ronghui
AU  - He R
AD  - Hangzhou YITU Healthcare Technology Co., Ltd., Hangzhou, China.
FAU - Xu, Yanjun
AU  - Xu Y
AD  - Department of Medical Oncology, The Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital) and Institute of Basic Medicine 
      and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - Luo, Taobo
AU  - Luo T
AD  - Department of Thoracic Surgery, The Cancer Hospital of the University of Chinese 
      Academy of Sciences(Zhejiang Cancer Hospital) and Institute of Basic Medicine and 
      Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - Jin, Kaixiu
AU  - Jin K
AD  - Hangzhou YITU Healthcare Technology Co., Ltd., Hangzhou, China.
FAU - Yuan, Wuzhou
AU  - Yuan W
AD  - Mingma Technologies Co., Ltd., Shanghai, China.
FAU - Zheng, Zengguang
AU  - Zheng Z
AD  - Department of Pathology, Tthe Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital) and Institute of Basic Medicine 
      and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - Liu, Lanxuan
AU  - Liu L
AD  - Hangzhou YITU Healthcare Technology Co., Ltd., Hangzhou, China.
FAU - Liang, Zebin
AU  - Liang Z
AD  - Hangzhou YITU Healthcare Technology Co., Ltd., Hangzhou, China.
FAU - Li, Ao
AU  - Li A
AD  - Mingma Technologies Co., Ltd., Shanghai, China.
FAU - Zheng, Zhiguo
AU  - Zheng Z
AD  - Zhejiang Cancer Research Institute, The Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Institute of Basic 
      Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - Li, Hui
AU  - Li H
AUID- ORCID: 0000-0001-8164-1624
AD  - Department of Medical Oncology, The Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital) and Institute of Basic Medicine 
      and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
LA  - eng
GR  - LQ21H160004/the Natural Science Foundation of Zhejiang Province/
GR  - 202143913/Zhejiang Medical technology program/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210615
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Aged
MH  - Antigens, Neoplasm/*genetics
MH  - Biomarkers, Tumor/genetics
MH  - Carcinoma, Non-Small-Cell Lung/*genetics
MH  - China
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*genetics
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Exome Sequencing
PMC - PMC8327700
OTO - NOTNLM
OT  - NSCLC
OT  - biomarker
OT  - neoantigen load
OT  - prognosis
OT  - whole exome sequencing
COIS- The authors declare that they have no competing interests.
EDAT- 2021/06/16 06:00
MHDA- 2021/12/22 06:00
PMCR- 2021/08/01
CRDT- 2021/06/15 07:17
PHST- 2021/05/15 00:00 [revised]
PHST- 2021/03/07 00:00 [received]
PHST- 2021/05/18 00:00 [accepted]
PHST- 2021/06/16 06:00 [pubmed]
PHST- 2021/12/22 06:00 [medline]
PHST- 2021/06/15 07:17 [entrez]
PHST- 2021/08/01 00:00 [pmc-release]
AID - TCA14046 [pii]
AID - 10.1111/1759-7714.14046 [doi]
PST - ppublish
SO  - Thorac Cancer. 2021 Aug;12(15):2170-2181. doi: 10.1111/1759-7714.14046. Epub 2021 
      Jun 15.